AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the Application.

LISTING OF CLAIM

- 1-12. (cancelled).
- 13. (previously presented) A compound according to Formula III,

or a pharmaceutically acceptable salt thereof, wherein:

- R^{la} is selected from halogen, lower perfluoroalkyl, -NO₂, and optionally substituted C₁.

 4alkyl; and R^{lb} is selected from halogen, -N(R^5) R^5 , -SR 5 , perfluoroalkyl, and optionally substituted lower alkyl;
- R³ is independently selected from -H, halogen, trihalomethyl, -CN, -NO2, -OR5, -N(R5)OR5, -ON(R5)R5, -N(R5)N(R5)R5, -N(R5)N(R5)R5, -S(O)₀₂R5, -SO₂N(R5)R5, -CO₂R5, -CO₃N6, -N(R5)SO₂R5, -N(R5)CO₃R5, -N(R5

R5a is H:

- each R⁵ is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or
- two of R⁵, together with the atom or respective atoms to which they are attached, can combine to form an optionally substituted three- to seven-membered heterocyclic;
- each R⁶ is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -NH₂,
 -OR⁵, -N(R⁵)R⁵, -S(O)₀₋₂R⁵, -SO₂N(R⁵)R⁵, -CO₂R⁵, -C(O)N(R⁵)R⁵, -N(R⁵)SO₂R⁵,
 -N(R⁵)C(O)R⁵, -N(R⁵)CO₂R⁵, -C(O)R⁵, optionally substituted lower alkyl,
 optionally substituted aryl, optionally substituted heterocyclyl, optionally
 substituted heterocyclylalkyl, and optionally substituted arylalkyl; or
- two of R⁶, together with the atom or atoms to which they are attached, can combine to form one of an optionally substituted three to seven-membered alicylic, and an optionally substituted three to seven-membered heteroalicylic;
- each R⁷ is independently selected from -H, -CN, -NO₂, -N(R⁵)R⁵, -OR⁵, -S(O)₀₋₂R⁵, -SO₂N(R⁵)R⁵, -CO₂R⁵, optionally substituted lower alkyl, optionally substituted lower alkenyl, and optionally substituted lower alkenyl; or
- R⁵ and R⁷, together with the atom or atoms to which they are attached, can combine to form a five- to seven-membered optionally substituted heterocyclyl;
- each of X and Y is independently selected from -C(=O)-, -C(R⁶)R⁶-, -O-, -N(R⁵)-,
 -C(=NR⁷)-, and -S(O)₀₋₂-; provided when X is -O- or -N(R⁵)-, then Y cannot
 contain phenyl, napthyl, cyclohexyl, dihydronapthyl tetrahydronapthyl, or a fiveto six-membered heteroaryl, each optionally substituted; and
- Q is either =N- or =C(H)-.
- 14. (previously presented) The compound according to claim 13, wherein R^{la} is selected from -NO₂, halogen, perfluoroalkyl, haloalkyl, and optionally substituted $C_{\mathrm{l-2}}$ alkyl.

- 15. (original) The compound according to claim 14, wherein R³ is selected from optionally substituted -O-C_{1.4}alkyl, -O-C_{1.4}perfluoroalkyl, optionally substituted -N(H)C_{1.4}alkyl, optionally substituted -N(C_{1.4}alkyl)C_{1.4}alkyl, optionally substituted -S(O)_{0.2}-C_{1.4}alkyl, and optionally substituted -S(O)_{0.2}-C_{1.4}alkyl, and optionally substituted -S(O)_{0.2}-C_{1.4}alkyl.
- 16. (original) The compound according to claim 15, wherein Y is either -N(H)- or - $C(R^6)R^6$ -.
- (original) The compound according to claim 16, wherein X is selected from -O-,-N(R⁵)- and -S-.
- 18. (original) The compound according to claim 17, wherein Y is $-C(R^6)R^6$; wherein each R^6 is independently selected from -H, halogen, trihalomethyl, -NH₂, optionally substituted -O-C_{1.4}alkyl, optionally substituted -N(H)C_{1.4}alkyl, optionally substituted -S-C_{1.4}alkyl, optionally substituted lower alkyl, optionally substituted heterocyclylalkyl.
- 19. (original) The compound according to claim 18, wherein Y is $-C(H)R^6$; wherein R^6 is independently selected from -H, halogen, trihalomethyl, -NH₂, optionally substituted -O-C₁₋₄alkyl, optionally substituted -N(H)C₁₋₄alkyl, optionally substituted -S-C₁₋₄alkyl, optionally substituted lower alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclylalkyl.
- 20. (original) The compound according to claim 19, wherein Q is =C(H)-.
- 21-28. (cancelled)
- 29. (previously presented) The compound according to claim 13, wherein R^{1a} is selected from halo, lower perfluoroalkyl, -NO₂, and optionally substituted C_{1-4} alkyl.
- 30-33. (Cancelled)
- 34. (previously presented) A compound selected from Table 3.

Entry	Name Table	Structure
1	2-[(3-cyano-4,6-dimethyl-5- nitropyridin-2-yl)oxy]-N-[3- (trifluoromethyl)phenyl]acetamide	O ₂ N CN CF ₃
5	N ² -[2-amino-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	S CF3
7	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [3-(methyloxy)phenyl]acetamide	H ₂ N N S N H O
9	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- (4-chlorophenyl)acetamide	H ₂ N N S CI
11	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- (3-chlorophenyl)acetamide	H ₂ N N CI

Entry	Name	Structure
14	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3-(trifluoromethyl)phenyl]acetamide	H ₂ N N F F
16	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- methyl-N-[3- (trifluoromethyl)phenyl]acetamide	H ₂ N N CF ₃
17	N ² -[4-amino-6-(methylthio)-1,3,5- triazin-2-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	S N H ₂ N CF ₃
20	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
30	2-amino-4-({2-[2,5- bis(methyloxy)phenyl]-2- oxoethyl}thio)-6- (methylthio)pyrimidine-5-carbonitrile	H ₂ N N S
31	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [4-fluoro-3- (trifluoromethyl)phenyl]acetamide	S CN H ₂ N CF ₃

Entry	Name	Structure
34	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [4-chloro-3- (trifluoromethyl)phenyl]acetamide	S CN H CF3
35	2-amino-4-(methylthio)-6-({2-oxo-1-[3-(trifluoromethyl)phenyl]pyrrolidin-3-yl}thio)pyrimidine-5-carbonitrile	H ₂ N N CF ₃
36	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [6-(trifluoromethyl)pyridin-2- yl]acetamide	H ₂ N N S N N CF ₃
37	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [4-(trifluoromethyl)pyridin-2- yl]acetamide	S CF ₃
41	2-{[2-(acetylamino)-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [3-(trifluoromethyl)phenyl]acetamide	S N H S F F
42	(2S)-2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3- (trifluoromethyl)phenyl]propanamide	-s N F F F HN-W S N S N S N S N S N S N S N S N S N S

Entry	Name	Structure
45	2-{[2-amino-5-formyl-6- (methylamino)pyrimidin-4-yl]thio}- N-[3- (trifluoromethyl)phenyl]acetamide	NH2 NH2 SH
46	2-{[2-amino-5-formyl-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3-(trifluoromethyl)phenyl]acetamide	NH2 N N N N N N N N N N N N N N N N N N N
47	2-{[4-amino-6-(methylthio)-1,3,5- triazin-2-yl]oxy}-N-[3- (trifluoromethyl)phenyl]acetamide	S O H F F
54	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [2-(methyloxy)-5- (trifluoromethyl)phenyl]acetamide	SHANN NAME OF THE PROPERTY OF
55	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [2-chloro-5- (trifluoromethyl)phenyl]acetamide	H ₂ N ₂ N ₃ N ₄ N ₄ N ₅

Entry	Name	Structure
58	N²-[2-amino-5-[(E)- hydrazonomethyl]-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	SH2 NH2 NH2 NH2
59	N ² -[2-amino-5-[(E)- (hydroxyimino)methyl]-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	H-Z-H N-Z-H
60	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	SH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 N
61	2-{[2-amino-5-cyano-6- (methylamino)pyrimidin-4-yl]thio}- N-[3- (trifluoromethyl)phenyl]acetamide	NH N H ₂ N S S S F F
62	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [2-amino-5- (trifluoromethyl)phenyl]acetamide	H ₂ N N S N H NH ₂

Entry	Name	Structure
63	2-amino-4-(methylthio)-6-({[6- (trifluoromethyl)-1H-benzimidazol-2- yl]methyl}thio)pyrimidine-5- carbonitrile	H ₂ N S N F F
64	2-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]hydrazinecar boxamide	S I I N I N I N I N I N I N I N I N I N
65	N ² -[5-cyano-2-(methylamino)-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
66	2-{[2-amino-5-cyano-6- (dimethylamino)pyrimidin-4-yl]thio}- N-[3- (trifluoromethyl)phenyl]acetamide	H ₂ N S S F
67	(S)-1-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]prolinamide	S N O F F F
68	(2R)-2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3- (trifluoromethyl)phenyl]propanamide	-s N F F F F F F F F F F F F F F F F F F

Entry	Name	Structure
69	1-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3- (trifluoromethyl)phenyl]cyclopropane carboxamide	-S O F F F
70	(2S)-2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-3- methyl-N-[3- (trifluoromethyl)phenyl]butanamide	H ₂ N O HN F F
72	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2- methyl-N-[3- (trifluoromethyl)phenyl]glycinamide	S N H ₂ N N N N F F
73	1-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]amino}- N-[3- (trifluoromethyl)phenyl]cyclopropane carboxamide	-S HO F F
74	N ² -[2-amino-5-cyano-6- (methylsulfinyl)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	N H ₂ N N H F F

Entry	Name	Structure
75	N²-[2-amino-5-cyano-6- (methylsulfonyl)pyrimidin-4-yl]-N- [3-(trifluoromethyl)phenyl]-L- alaninamide	H ₂ N N H F F
76	N ² -(5-cyano-2-morpholin-4- ylpyrimidin-4-yl)-N-[3- (trifluoromethyl)phenyl]glycinamide	N H F F
78	N²-[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	H_2N N N N N N N N N N
79	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[2- (methyloxy)-5- (trifluoromethyl)phenyl]-L- alaninamide	N N CF3
80	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[2- chloro-5-(trifluoromethyl)phenyl]-L- alaninamide	S N H ₂ N CF ₃
83	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-D- alaninamide	S N H ₂ N CF ₃

Entry	Name	Structure
84	2-[(2-amino-5-cyano-6-morpholin-4-ylpyrimidin-4-yl)thio]-N-[3- (trifluoromethyl)phenyl]acetamide	NH ₂ NH ₂ S
85	(R)-1-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]prolinamide	S N O F F F
86	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- ornithinamide	S CN NH2 H ₂ N N N O CF ₃
87	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2-[2- (dimethylamino)ethyl]-N-[3- (trifluoromethyl)phenyl]glycinamide	S CN H ₂ N CF ₃
88	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	H ₂ N H CF ₃

Entry	Name	Structure
89	N ² -(2,6-diamino-5-cyanopyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	NH ₂ CN H CF ₃
90	N ² -(2-amino-5-cyanopyrimidin-4-yl)- N-[3-(trifluoromethyl)phenyl]-L- alaninamide	H ₂ N N N N CF ₃
91	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2- methyl-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	S CN CF3
93	2-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-1,2- dimethyl-N-[3- (trifluoromethyl)phenyl]hydrazinecar boxamide	H ₂ N
94	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- amino-5-(trifluoromethyl)phenyl]-L- alaninamide	S CN H ₂ N CF ₃
95	ethyl [1-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-2-({[3- (trifluoromethyl)phenyl]amino}carbo nyl)hydrazino]acetate	S CN CF3

Entry	Name	Structure
96	2-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-2- methyl-N-[3- (trifluoromethyl)phenyl]hydrazinecar boxamide	S CN CF3
100	N ² -[5-cyano-2-(methylthio)pyrimidin-4-yl]- N-[3-(trifluoromethyl)phenyl]glycinamide	S N T CF3
101	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2- (tetrahydro-2H-pyran-4-ylmethyl)-N-[3- (trifluoromethyl)phenyl]glycinamide	S CN H ₂ N N N CF ₃
102	N ² -(2-amino-5-cyano-6-{[2- (dimethylamino)ethyl]oxy)pyrimidin-4-yl)- N-[3-(trifluoromethyl)phenyl]-L- alaninamide	H ₂ N N N CF ₃
103	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-6-{[(1,1- dimethylethyl)oxy]carbonyl}-N-[3- (trifluoromethyl)phenyl]-L-lysinamide	NH ₂ OF ₃ CF ₃ CF ₃ NH ₂ OF ₃ NH ₄ OF ₄ OF ₅ NH ₄ OF ₅ OF ₅ NH ₄ OF ₅

Entry	Name	Structure
104	2-amino-4-(methylthio)-6-(methyl((1S)-1- [6-(trifluoromethyl)-1H-benzimidazol-2- yl]ethyl)amino)pyrimidine-5-carbonitrile	NC NH2 CF3
105	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl)-N-2-[2- (tetrahydro-2H-pyran-4-yl)ethyl]-N-[3- (trifluoromethyl)phenyljglycinamide	S CF ₃
106	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-y]-N-[3-([2- (diethylamino)ethyl]amino}-5- (trifluoromethyl)phenyl]-L-alaninamide	NH ₂ NH S CN H CF ₃
107	2-amino-4-(methylthio)-6-({(1S)-1-[6- (trifluoromethyl)-1H-benzimidazol-2- yl]ethyl)amino)pyrimidine-5-carbonitrile	-S N H F F
108	2-(2-amino-5-cyano-6-[1-(3- trifluoromethyl-phenylcarbamoyl)-1S- ethylamino]-pyrimidin-4-ylamino)-N-(3- trifluoromethyl-phenyl)-2S-propionamide	HN CF ₃ H ₂ N N N CF ₃ CF ₃

Entry	Name	Structure
109	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2-methyl-N- (3-methylphenyl)glycinamide	NH2 N N N N N N N N N N N N N N N N N N
110	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2-methyl-N- [3-(1-methylethyl)phenyl]glycinamide	SH2 SH2 NH2 NH2
111	N ² -[2-amino-5-cyano-6- (methythio)pyrimidin-4-yi]-N-5- [inino(nitroamino)methyl]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	NH ₂ NH ₂ NNO ₂ NCF ₃
112	methyl 3-{{N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yi]-L- alanyl}amino)-5-{trifluoromethyl)benzoate	NH2 NH2 NH2 CF3 CO ₂ CH3
113	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-{3- nitrophenyl)-L-alaninamide	SH2 SHO2
114	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-lysinamide	NH_2

Entry	Name	Structure
115	N ² -[2-amino-5-cyano-6- (propyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-alaninamide	NH ₂ NH ₂ CF ₃
117	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-argininamide	NH ₂ NH ₂ NH S NH CF ₃
118	N²-[2-amino-5-cyano-6- (methylsulfinyl)pyrimidin-4-yi]-N-2-methyl- N-[3-(trifluoromethyl)phenyl]-L- alaninamide	NH2 N N N N CF3
119	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-N-2-methyl-N- [3-(trifluoromethyl)phenyl]-L-alaninamide	NH ₂ NH ₂ NH ₂ CF ₃
120	$N^2\hbox{-[2-amino-5-cyano-6-} \\ (propyloxy)pyrimidin-4-yl]-N-2-methyl-N-[3-(trifluoromethyl)phenyl]-L-alaninamide$	NH ₂ NH ₂ NH ₂ NH ₂ CF ₃
121	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-2-methyl-N-[3- (trifluoromethyl)phenyl]-L-alaninamide	NH ₂ NH ₂ NH ₂ CF ₃

Table 3

Entry	Name	Structure
122	N ² -{2-amino-5-cyano-6-[(1- methylethyl)oxy]pyrimidin-4-yi}-N-[3- (trifluoromethyl)phenyl]-L-alaninamide	NH ₂ N N N N CF ₃
123	N-5-acetyl-N-2-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	SH2 CF3
124	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-(3- aminophenyl)-L-alaninamide	SH-SH-SH-SH-SH-SH-SH-SH-SH-SH-SH-SH-SH-S
125	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-L- alany)}amino-N-[2-(dimethylamino)ethyl]- 5-(trifluoromethyl)benzamide	-Z - H - C - C - C - C - C - C - C - C - C
126	2-(methyloxy)ethyl ((4S)-4-[[2-amino-5- cyano-6-(methylthio)pyrimidin-4- yl]amino)-5-oxo-5-[[3- (trifluoromethyl)phenyl]amino)pentyl)carb amate	NH ₂ NH ₂ NH ₂ NH ₂ NH ₂ NH ₃

Entry	Name	Structure
127	2-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-N-[3- (trifluoromethyl)phenyl]hydrazinecarboxa mide	NH2 CN H H CF3
128	1,1-dimethylethyl ((4S)-4-{[2-amino-5- cyano-6-(ethyloxy)pyrimidin-4-yl]amino}- 5-oxo-5-{[3- (trifluoromethyl)phenyl]amino)pentyl)carb amate	NH2 CF3
130	3-{{N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-methyl-L- alany}amino)-N-[2- (dimethylamino)ethyl]-5- (trifluoromethyl)benzamide	H ₂ N CH ₃ Chiral H ₂ N CH ₃ H CH ₃ H CH ₃ H CH ₃ O H ₃ C·N·CH ₃
131	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl)-N-methyl-L- alanyl)amino-N-[3-(4-methylpiperazin-1- yl)propyl]-5-(trifluoromethyl)benzamide	S.CH ₃ Chiral Ohiral

Entry	Name	Structure
132	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2~-methyl- N-[3-[(trifluoromethyl)oxy]phenyl]-L- alaninamide	S.CH ₃ N CHrall
133	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-(3- bromophenyl)-N~2~-methyl-L- alaninamide	H ₃ C·S CNCH ₃ H H ₂ N N N N N N N N N N N N N N N N N N N
134	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-y]-N-{2-[[2- (dimethylamino)ethy]0xy]-5- [(trifluoromethyl)oxy]phenyl-N-2 methyl-L-alaninamide	S.CH ₃ N Chiral Chiral N Chiral N CH ₃ O F F H ₃ C'N·CH ₃
135	3-{{N-[2-amino-5-cyano-6- (methythio)pyrimidin-4-ylp-N-methyl-L- alany]}amino-N-{2-morpholin-4-ylethyl)- 5-{trifluoromethyl)benzamide	S.CH ₃ Chiral Chiral Chiral Chiral Ch ₃ Ch

Entry	Name	Structure
136	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yi]-N2~-methyl-N- [3-(trifluoromethyl)phenyl]-L-lysinamide	CH ₃ NH ₂ Chiral
137	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-y]-N-[3-[2- (dimethylamino)ethyl]oxy}-5- (trifluoromethyl)phenyl]-L-alaninamide	Chiral N CH ₃ H CH ₃ H F F F CH ₃ CH ₃ CH ₃ CH ₃ CH ₃ CH ₃
138	(2S)-2-{[2-amino-5-cyano-6- (methylthio)pyrimldin-4-yl]amino)-3-oxo- 3-{[3-(trifluoromethyl)phenyl]amino)propyl acetate	H ₃ C·S CH ₃ Chiral
139	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-y]-N~1~-[3- (trifluoromethyl)phenyl]-L-glutamamide	H ₃ C·S H ₂ N O CHrist N N N CF ₃
140	. 2-[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyllhydrazinecarboxa mide	H ₃ C. O N H H F F F

Entry	Name	Structure
141	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl)-L- alanyl)amino)-N-hydroxy-5- (trifluoromethyl)benzamide	S.CH ₃ N Chiral N N N CF ₃ H ₂ N N N O O O O
142	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-3- (dimethylamino)-N-[3- (trifluoromethyl)phenyl]-L-alaninamide	H ₃ C·s CH ₃ CH ₃ F F F F F F F F F F F F F F F F F F F
143	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-5-morpholin-4- yl-N-[3-(trifluoromethyl)phenyl]-L- norvalinamide	H ₃ C·s H ₂ N H F F
144	N ² -[2-amino-5-cyano-6- (methyithio)pyrimidin-4-yl]-N-5~-[2- (methyloxy)ethyl]-N-[3- (trifluoromethyl)phenyl]-L-omithinamide	S.CH, NH NH CF ₃

Table 3

Entry	Name	Structure
145	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-L- alanyl}amino)-5-(trifluoromethyl)benzoic acid	H ₂ N CF ₃ H
146	methyl N~2~-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yi]-N-[3- (trifluoromethyl)phenyl]-L-alpha- gutaminate	H ₃ C·SH ₃ C·OOO Chiral
147	N ⁵ -(aminocarbonyl)-N~2~-[2-amino-5- oyano-6-(methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	SMe NH FF
148	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	CHrail NH2 NH2 FF
149	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-y]-N-[3- (trifluoromethyl)phenyl]-L-alpha-glutamine	H ₃ C·s HO O Chiral

Table 3

Entry	Name	Structure
150	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-N-[3- (trifluoromethyl)phenyl]-L-serinamide	CHa Chial
151	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-O- (phenylmethyl)-N-[3- (trifluoromethyl)phenyl]-L-serinamide	CHral Chiral Chiral H ₂ N N N CF ₃
152	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-argininamide	CH ₃ H ₂ N NH Chiral
153	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2~-methyl- N ⁶ -{[(phenylmethyl)oxy]carbonyl]-N-[3- (trifluoromethyl)phenyl]-L-lysinamide	Chiral Chiral Chiral

Entry	Name	Structure
154	N-c-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-tyrosinamide	H ₃ C O CN H Chral
155	N ⁵ -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yi]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	H ₃ C. S N HN O NH ₂
156	N²-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-6-,N-6 dimethyl-N-[3-(trifluoromethyl)phenyl]-L- lysinamide	CH ₃ H ₃ C·N·CH ₃ Chiral
157	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-N-[3-[(4- methylpiperazin-1-yl)carbonyi]-5- (trifluoromethyl)phenyl]-L-alaninamide	Chiral Chiral Chiral Chiral Chiral

Table 3

Entry	Name	Structure
158	3-{{N-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-L-alany)amino)- N-{3-pyrrolidin-1-ylpropyl)-5- (trifluoromethyl)benzamide	Chiral Chiral Chiral Chiral N CH ₃ H CF ₃ HN O N N N N N N N N N N N N
159	3-{{N-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-L-alanylylamino)- N-(2-morpholin-4-ylethyl)-5- (trifluoromethyl)benzamide	CH ₃ Chiral
160	3-{{N-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-1-alany)Jamino)- N-[2-(dimethylamino)ethyl]-5- (trifluoromethyl)benzamide	Chiral Chiral Chiral Chiral CH ₃ H CF ₃ HN O H ₃ C·N·CH ₃

Table 3

Entry	Name	Structure
161	3-({N-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-1-alanyl}amino)- N-[3-(4-methylpiperazin-1-yl)propyl]-5- (trifluoromethyl)benzamide	CH ₃ Chiral N CH ₃ H CF ₃ H ₂ N N N CF ₃ HN O
162	N^2 -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-2methyl- N^6 -[((phenylmethyl)oxy]carbonyl]-N-[3- (trifluoromethyl)phenyl]-L-lysinamide	Chiral Chiral Chapter of the chapt
163	1,1-dimethylethyl ((4\$)-4-{[2-amino-5- cyano-6-(ethyloxy)pyrimidin-4-y]amino}- 5-oxo-5-{[3- (trifluoromethyl)phenyl]amino)pentyl)carb amate	CH ₃ ONH H ₂ N N H F F

Table 3			
Entry	Name	Structure	
164	(2S)-2-{[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yi]amino}-3-oxo-3- {[3-(trifluoromethyl)phenyl]amino}propyl acetate	CH ₃ Chiral	
165	phenylmethyl N~2~-{2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl,N-{3- (trifluoromethyl)phenyl)-L-alpha- glutaminate	Chiral CH ₃ CH ₃ CN H ₂ N CF ₃	
166	N ² , N ⁵ -diacetyl-N-2~-[2-(acetylamino)-5- cyano-6-(methylthio)pyrimidin-4-yi]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	S.CH3 NH CF3	
167	2-(methyloxy)ethyl ((4S)-4-[[2-amino-5- cyano-6-(methylthio)pyrimidin-4- yl[amino]-5-oxo-5-[[3- (trifluoromethyl)phenyl[amino]pentyl)carb amate	O O O CH ₃ Chrai	

Entry	Name	Structure
168	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-5-morpholin-4-yl- N-[3-(trifluoromethyl)phenyl]-L- norvalinamide	Chiral Ch
169	N-((4S)-4-{[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y amino)-5-oxo-5- {[3-{trifluoromethyl)phenyl]amino}pentyl)- N,N-dimethylmethanaminium	CH ₃ CH _{CH₃} Chiral
170	Methyl N ² -[2-amino-5-cyano-6- (ethyloxy)pyrinidin-4-yl-N-[3- (trifluoromethyl)phenyl]-L-alpha- glutaminate	CH ₃ Chiral OH ₃ COO H ₂ N H ₂ N Chiral
171	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-y]-N-6~,N-6~- dimethyl-N-[3-(trifluoromethyl)phenyl]-L- lysinamide	H ₃ C. _N .CH ₃ Chiral
172	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-2~-methyl-N- (3-{(trifluoromethyloxy)phenyl)-L- alaninamide	Chiral Chiral Chiral P Chiral

Entry	Name	Structure
173	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-alpha-glutamine	CH ₃ HO O Chiral
174	N~2~-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl-N-(3- bromophenyl)-N~2~-methyl-L- alaninamide	Chinal Ch
175	$N^2 \hbox{-} \{2\hbox{-amino-5-cyano-6-} \\ \hbox{(ethyloxy)pyrimidin-4-yi}-N^1 \hbox{-} \{3\hbox{-} \\ \hbox{(trifluoromethyl)phenyl}-L-glutamamide}$	CHrall CHrall CHrall CHrall CHrall CHrall CHrall CHrall CF3
176	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-3- (dimethylamino)-N-[3- (trifluoromethyl)phenyl]-L-alaninamide	CH ₃ CH ₃ H ₂ N-CH ₃ F _F
177	2-(2-amino-5-cyano-6- ethoxypyrimidin-4-ylamino)-5- hydrazinyl-5-oxo-N-(3- (trifluoromethyl)phenyl)pentanamide	CH ₃ ONH ₂ Chiral

Entry	Name	Structure
178	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-y]-3- (dimethylamino)-N-[3- (trifluoromethyl)phenyl]-L-alaninamide	H ₃ C. O Chiral
179	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-y]-N-[3-{[2- (dimethylamino)ethyl)oxy)-5- (trifluoromethyl)phenyl]-L-alaninamide	H ₂ N N H O F F CH ₃ CH ₃ CH ₃ CH ₃ CH ₃
180	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3-{[2- (dimethylamino)elyn)]oxy]-5- (trifluoromethyl)phenyl]-L-alaninamide	Chiral Chiral Chiral Chiral Chiral Chiral Chiral
181	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimldin-4-yl]-N-(3- bromophenyl)- N ² -methyl-L-alaninamide	H ₂ C·OCNH ₃ H H ₂ N N N N N Br

Entry	Name	Structure
182	phenylmethyl N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-alpha- glutarninate	H ₂ C. S CF ₃
183	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-O- (phenylmethyl)-N-[3- (trifluoromethyl)phenyl]-L-serinamide	H ₂ C.S CN O H CF ₃
184	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yll-N-5~,N~5~- bis[2-(methyloxy)ethy]-N-[3- (trifluoromethyl)phenyl]-L-omithinamide	S.CH3 NOCH3 H2N HOCF3
185	1,1-dimethylethyl ((4S)-4-{[2-amino-5- cyano-6-(methyloxy)pyrimidin-4- yljamino)-5-oxo-5-{[3- (trifluoromethyl)phenyljamino)pentyl)carb amate	H ₂ N N H O CH ₃ CFF ₃

Entry	Name	Structure
186	N ⁵ -acetyl- N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	CH ₃ O ₂ CH ₃ Chiral
187	N ⁵ ~-acetyl- N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yi]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	O CH ₃ Chral
188	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]- N ² -methyl-N- (3-[(trifluoromethyl)oxy]phenyl)-L- alaninamide	H ₂ N N CH ₃ N OCF ₃
189	methyl 3-{{N-{2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl}-L- alanyl}amino)-5-(trifluoromethyl)benzoate	H ₂ N N N CF ₃

Entry	Name	Structure
190	3-({N-[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-L- alanyl}amino)-N-[2-(dimethylamino)ethyl]- 5-(trifluoromethyl)benzamide	Chiral Chiral Chiral Chiral Chiral Chiral
191	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-3-morpholin-4- yl-N-[3-(trifluoromethyl)phenyl]-L- alaninamide	H ₂ N N H F F
192	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yi]-3-morpholin-4- yi-N-[3-(trifluoromethyl)phenyl]-L- alaninamide	H ₃ C. O Chiral
193	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-3-morpholin-4-yl- N-[3-(trifluoromethyl)phenyl]-L- alaninamide	CHrist
194	$N^{5}\text{-(aminocarbonyl)-}N^{2}\text{-[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3-(trifluoromethyl)phenyl]-L-ornithinamide}$	ONH ₂ Chral

Table 3

Table 3			
Entry	Name	Structure	
195	N-2~-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-D-lysinamide	NH ₂ Chrall	
196	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-N-[3- (trifluoromethyl)phenyl]-D-lysinamide	OEt NH ₂ Chiral	
197	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrlmidin-4-yl]-O-methyl-N-[3- (trifluoromethyl)phenyl]-L-serinamide	CH ₃ CH ₃ CH ₃ CH ₃ CH ₃ CH ₃ CF ₃	
198	N ² -[2-amino-5-cyano-6- (methylthio)pyrimkin-4-yl]-N-5~- (methylsutinoyl)-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	Chy Chiral O=\$=CO NH H ₂ N N N	

- 35. (previously presented) A pharmaceutical composition comprising the compound according to claims 13 and a pharmaceutically acceptable carrier.
- 36. (cancelled).

Attorney Docket No. 05-937-B5/EX04-066C-US USSN: 10/576,653 Page 38 of 43

- 37. (cancelled)
- 38. (cancelled)
- 39. (cancelled)
- 40. (currently amended) A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of a composition comprising a compound according to claim 13, wherein said diseases or disorders are selected from cancer, rheumatoid arthritis, graft-host diseases, multiple sclerosis, psoriasis, artheroscrosis, myocardioinfarction, ischemia, stroke, diabetes, obesity, hypercholesterolemia, interbowel diseases, osteoarthritus, macular degeneration and diabetic retinopathy.
- 41. (cancelled)
- 42. (cancelled)
- 43. (cancelled)